Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesoblast (MESO) Cash & Equivalents: 2015-2025

Historic Cash & Equivalents for Mesoblast (MESO) over the last 11 years, with Jun 2025 value amounting to $161.6 million.

  • Mesoblast's Cash & Equivalents rose 156.67% to $161.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $161.6 million, marking a year-over-year increase of 156.67%. This contributed to the annual value of $161.6 million for FY2025, which is 156.67% up from last year.
  • Mesoblast's Cash & Equivalents amounted to $161.6 million in FY2025, which was up 156.67% from $63.0 million recorded in FY2024.
  • Mesoblast's Cash & Equivalents' 5-year high stood at $161.6 million during FY2025, with a 5-year trough of $60.4 million in FY2022.
  • In the last 3 years, Mesoblast's Cash & Equivalents had a median value of $71.3 million in 2023 and averaged $98.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 55.84% in 2022, then spiked by 156.67% in 2025.
  • Mesoblast's Cash & Equivalents (Yearly) stood at $136.9 million in 2021, then plummeted by 55.84% to $60.4 million in 2022, then climbed by 17.98% to $71.3 million in 2023, then decreased by 11.72% to $63.0 million in 2024, then skyrocketed by 156.67% to $161.6 million in 2025.